Cargando…
Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies
Lung cancer patients are at heightened risk for developing COVID-19 infection as well as complications due to multiple risk factors such as underlying malignancy, anti-cancer treatment induced immunosuppression, additional comorbidities and history of smoking. Recent literatures have reported a sign...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IMSS. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670900/ https://www.ncbi.nlm.nih.gov/pubmed/33257051 http://dx.doi.org/10.1016/j.arcmed.2020.11.006 |
_version_ | 1783610828438634496 |
---|---|
author | Baburaj, Gayathri Thomas, Levin Rao, Mahadev |
author_facet | Baburaj, Gayathri Thomas, Levin Rao, Mahadev |
author_sort | Baburaj, Gayathri |
collection | PubMed |
description | Lung cancer patients are at heightened risk for developing COVID-19 infection as well as complications due to multiple risk factors such as underlying malignancy, anti-cancer treatment induced immunosuppression, additional comorbidities and history of smoking. Recent literatures have reported a significant proportion of lung cancer patients coinfected with COVID-19. Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management. The rationale of this review is to identify potential drug-drug interactions (DDIs) occurring in lung cancer patients receiving lung cancer medications and repurposed COVID-19 drugs using Micromedex and additional literatures. This review has identified several potential DDIs that could occur with the concomitant treatments of COVID-19 repurposed drugs and lung cancer medications. This information may be utilized by the healthcare professionals for screening and identifying potential DDIs with adverse outcomes, based on their severity and documentation levels and consequently design prophylactic and management strategies for their prevention. Identification, reporting and management of DDIs and dissemination of related information should be a major consideration in the delivery of lung cancer care during this ongoing COVID-19 pandemic for better patient outcomes and updating guidelines for safer prescribing practices in this coinfected condition. |
format | Online Article Text |
id | pubmed-7670900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | IMSS. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76709002020-11-18 Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies Baburaj, Gayathri Thomas, Levin Rao, Mahadev Arch Med Res Review Article Lung cancer patients are at heightened risk for developing COVID-19 infection as well as complications due to multiple risk factors such as underlying malignancy, anti-cancer treatment induced immunosuppression, additional comorbidities and history of smoking. Recent literatures have reported a significant proportion of lung cancer patients coinfected with COVID-19. Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management. The rationale of this review is to identify potential drug-drug interactions (DDIs) occurring in lung cancer patients receiving lung cancer medications and repurposed COVID-19 drugs using Micromedex and additional literatures. This review has identified several potential DDIs that could occur with the concomitant treatments of COVID-19 repurposed drugs and lung cancer medications. This information may be utilized by the healthcare professionals for screening and identifying potential DDIs with adverse outcomes, based on their severity and documentation levels and consequently design prophylactic and management strategies for their prevention. Identification, reporting and management of DDIs and dissemination of related information should be a major consideration in the delivery of lung cancer care during this ongoing COVID-19 pandemic for better patient outcomes and updating guidelines for safer prescribing practices in this coinfected condition. IMSS. Published by Elsevier Inc. 2021-04 2020-11-17 /pmc/articles/PMC7670900/ /pubmed/33257051 http://dx.doi.org/10.1016/j.arcmed.2020.11.006 Text en © 2020 IMSS. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Baburaj, Gayathri Thomas, Levin Rao, Mahadev Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies |
title | Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies |
title_full | Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies |
title_fullStr | Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies |
title_full_unstemmed | Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies |
title_short | Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies |
title_sort | potential drug interactions of repurposed covid-19 drugs with lung cancer pharmacotherapies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670900/ https://www.ncbi.nlm.nih.gov/pubmed/33257051 http://dx.doi.org/10.1016/j.arcmed.2020.11.006 |
work_keys_str_mv | AT baburajgayathri potentialdruginteractionsofrepurposedcovid19drugswithlungcancerpharmacotherapies AT thomaslevin potentialdruginteractionsofrepurposedcovid19drugswithlungcancerpharmacotherapies AT raomahadev potentialdruginteractionsofrepurposedcovid19drugswithlungcancerpharmacotherapies |